Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases

Current Cancer Drug Targets

Volumn 10, Issue 7, 2010, Pages 649-659

  Salerno, M ^a   Cenni, E ^a   Fotia, C ^a   Avnet, S ^a   Granchi, D ^a   Castelli, F ^b   Micieli, D ^b   Pignatello, R ^b   Capulli, M ^c   Rucci, N ^c   Angelucci, A ^c   Del Fattore, A ^c   Teti, A ^c   Zini, N ^a   Giunti, A ^a,d   Baldini, N ^a,d  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bisphosphonates; Bone targeting; Doxorubicin; Drug delivery system; Nanoparticles; Osteolysis; Skeletal metastases

Indexed keywords

DOXORUBICIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOLYSIS; TRANSMISSION ELECTRON MICROSCOPY;

EID: 78649283150     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910793605767     Document Type: Article

References (54)

1. Reich, C. D. Advances in the treatment of bone metastases. Clin. J. Oncol. Nurs. 2003, 7, 641-646.
2. Aaron, A. D. Treatment of metastatic adenocarcinoma of the pelvis and the extremities. J. Bone Joint. Surg. Am. 1998, 80, 763-764.
3. Guise, T. A. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat. Rev. 2008, 34, S19-24.
4. Michigami, T. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 2001, 61, 1637-1644.
5. Solomayer, E. F.; Diel, I. J.; Meyberg, G. C.; Gollan, C.; Bastert, G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res. Treat. 2000,59, 271-278.
6. Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, 12, 6243s-6249s.
7. Lipton, A. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone. Cancer Treat. Rev. 2008, 34(Suppl 1), S25-30.
8. Riccio, A. I.; Wodajo, F. M.; Malawer, M. Metastatic carcinoma of the long bones. Am. Fam. Physician 2007, 76, 1489-1494.
9. Clark, J. C.; Dass, C. R.; Choong, P. F. Current and future treatments of bone metastases. Expert. Opin. Emerg. Drugs 2008, 13, 609-627.
10. Shea, J. E.; Miller, S. C. Skeletal function and structure: implications for tissue-targeted therapeutics. Adv. Drug Deliv. Rev. 2005, 57, 945-957.
11. Adams, J. D.; Flora, K. P.; Goldspiel, B. R.; Wilson, J. W.; Arbuck, S. G.; Finley, R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr. 1993,15, 141-147.
12. Albini, A.; Pennesi, G.; Donatelli, F.; Cammarota, R.; De Flora, S.; Noonan, D. M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010, 102, 14-25.
13. Richardson, D. S.; Johnson, S. A. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev. 1977, 11, 201-223.
14. Northfelt, D. W.; Dezube, B. J.; Thommes, J. A.; Miller, B. J.; Fischl, M. A.; Friedman-Kien, A.; Kaplan, L. D.; Du Mond, C.; Mamelok, R. D.; Henry, D. H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised phase III clinical trial. J. Clin. Oncol. 1998, 16, 2445-2551.
15. McMenemin, R.; Macdonald, G.; Moffat, L.; Bissett, D. A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation. Invest. New Drugs 2002, 20, 331-337.
16. Pastorino, F.; Brignole, C.; Marimpietri, D.; Sapra, P.; Moase, E. H.; Allen, T. M.; Ponzoni, M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003, 63, 86-92.
17. Rawat, M.; Singh, D.; Saraf, S.; Saraf, S. Nanocarriers: Promising vehicle for bioactive drugs. Biol. Pharm. Bull. 2006, 29, 1790-1798.
18. Emerich, D. F.; Thanos, C. G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target 2007, 15, 163-183.
19. Maeda, H.; Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989,6, 193-210.
20. Sinha, R.; Kim, G. J.; Nie, S.; Shin, D. M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5, 1909-1917.
21. Tiwiri, S. B.; Amuji, M. M. A review of nanocarrier-based CNS delivery system. Curr. Drug Deliv. 2006, 3, 219-232.
22. Barbu, E.; Molnàr, E.; Tsibouklis, J.; Górecki, D. C. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert. Opin. Drug Deliv. 2009, 6, 553-565.
23. 3H-etidronate in rat and mouse bones. Bone 1996, 19, 281-290.
24. Hirabayashi, H.; Fujisaki, J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 2003, 42, 1319-1330.
25. Wang, D.; Miller, S. C.; Kopecková, P.; Kopecek, J. Bonetargeting macromolecular therapeutics. Adv. Drug Deliv. Rev. 2005,57, 1049-1076.
26. Russel, R. G. Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci. 2006, 1068, 367-401.
27. Markovsky, E.; Koroukhov, N.; Golomb, G. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine 2007, 2, 545-553.
28. Uludag, H.; Yang, J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol. Prog. 2002, 18, 604-611.
29. Choi, S. W.; Kim, J. H. Design of surface-modified poly (D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J. Control Release 2007, 122, 24-30.
30. Miller, K.; Erez, R.; Segal, E.; Shabat, D.; Satchi-Fainaro, R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. Engl. 2009, 48, 2949-2954.
31. Cenni, E.; Granchi, D.; Avnet, S.; Fotia, C.; Salerno, M.; Micieli, D.; Sarpietro, M.G.; Pignatello, R.; Castelli, F.; Baldini, N. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 2008, 29, 1400-1411.
32. Pignatello, R.; Cenni, E.; Micieli, D., Fotia, C.; Salerno, M.; Granchi, D.; Avnet, S.; Sarpietro, M. G.; Castelli, F.; Baldini, N. A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate. Nanomedicine 2009, 4, 161-175.
33. Baldini, N.; Scotlandi, K.; Serra, M.; Kusuzaki, K.; Shikita, T.; Manara, M. C.; Maurici, D.; Campanacci, M. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. J. Cancer Res. Clin. Oncol. 1992, 119, 121-126.
34. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
35. Susa, M.; Iyer, A. K.; Ryu, K.; Hornicek, F. J.; Mankin, H.; Amiji, M. M.; Duan, Z. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer 2009, 16, 9, 399-410.
36. Ottewell, P. D.; Woodward, J. K.; Lefley, D. V.: Evans, C. A.; Coleman, R. E.; Holen, I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol. Cancer Ther. 2009, 8, 2821-2832.
37. Pan, H.; Sima, M.; Kopecková, P.; Wu, K.; Gao, S.; Liu, J.; Wang, D.; Miller, S. C.; Kopecek, J. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-ydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol. Pharm. 2008, 5, 548-558.
38. Zunino, F.; Capranico, G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 1990, 5, 307-317.
39. Calabresi, P.; Chabner, A. In Goodman and Gilman's the pharmacological basis of therapeutics. Goodman Gilman, A.; Rall, T. W.; Nies, A. S.; Taylor, P. Eds. Chemotherapy of neoplastic diseases. The McGraw-Hill Companies: New York, 1991, pp. 1202-1263.
40. Baldini, N.; Scotlandi, K.; Serra, M.; Shikita, T.; Zini, N.; Ognibene, A.; Santi, S.; Ferracini, R.; Maraldi, N. M. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur. J. Cell Biol. 1995, 68, 226-239.
41. Yu, D. S.; Chang, S. Y.; Ma, C. P. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br. J. Urol. 1998,82, 544-547.
42. Baldini, N. Multidrug resistance--a multiplex phenomenon. Nat. Med. 1997, 3, 378-380.
43. Schuurhuis, G. J.; Broxterman, H. J.; de Lange, J. H.; Pinedo, H. M.; van Heijningen, T. H.; Kuiper, C. M.; Scheffer, G. L.; Scheper, R. J.; van Kalken, C. K.; Baak, J. P.; Lankelmal, J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J. Cancer 1991, 64, 857-61.
44. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002,16, 1217-1226.
45. Vasir, J. K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug. Deliv. Rev. 2007, 59, 718-728.
46. Avnet, S.; Longhi, A.; Salerno, M.; Halleen, J. M.; Perut, F.; Granchi, D.; Ferrari, S.; Bertoni, F.; Giunti, A.; Baldini, N. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int. J. Oncol. 2008, 33, 1231-1238.
47. Sawada, K.; Morishige, K.; Tahara, M.; Kawagishi, R.; Ikebuchi, Y.; Tasaka, K.; Murata, Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res. 2002, 62, 6015-6020.
48. Rucci, N.; Recchia, I.; Angelucci, A.; Alamanou, M.; Del Fattore, A.; Fortunati, D.; Susa, M.; Fabbro, D.; Bologna, M.; Teti, A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J. Pharmacol. Exp. Ther. 2006, 318, 161-172.
49. Crnalic, S.; Häkansson, I.; Boquist, L.; Löfvenberg, R.; Brostrom, L. A. A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin. Exp. Metastasis 1997, 15, 164-172.
50. Rosol, T. J.; Tannehill-Gregg, S. H.; LeRoy, B. E.; Mandl, S.; Contag, C. H. Animal models of bone metastasis. Cancer 2003, 97, 748-757.
51. Fromigue, O.; Lagneaux, L.; Body, J. J. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 2000, 15, 2211-2221.
52. Kubista, B.; Trieb, K.; Sevelda, F.; Toma, C.; Arrich, F.; Heffeter, P.; Elbling, L.; Sutterlüty, H.; Scotlandi, K.; Kotz, R.; Micksche, M.; Berger, W. Anticancer effects of zoledronic acid against human osteosarcoma cells. J. Orthop. Res. 2006, 24, 1145-1152.
53. Clézardin, P.; Ebetino, F. H.; Fournier, P. G. J. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005, 65, 4971-4974.
54. Santini, D.; Schiavon, G.; Angeletti, S.; Vincenzi, B.; Gasparro, S.; Grilli, C.; La Cesa, A.; Virzí, V.; Leoni, V.; Budillon, A.; Addeo, S. R.; Caraglia, M.; Dicuonzo, G.; Tonini, G. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs? Recent Pat. Anticancer Drug Discov. 2006, 1, 383-396.